Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 87(02): 352-353
DOI: 10.1055/s-0037-1613004
DOI: 10.1055/s-0037-1613004
Letters to the Editor
Single-dose Pharmacokinetics of Porcine Factor VIII (Hyate C)
Further Information
Publication History
Received
20 June 2001
Accepted after resubmission
15 October 2001
Publication Date:
13 December 2017 (online)
-
References
- 1 Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG. Clinical experience with polyelectrolyte-fractionated porcine FVIII concentrate in the treatment of haemophiliacs with antibodies to FVIII. Blood 1984; 63: 31-41.
- 2 Efficacy, safety and treatment cost considerations. Workshop WFH, Dublin, Ireland, 28 June 1996: Porcine Factor VIII: its role in the management of congenital and acquired inhibitors. Haemophilia 1997; 03 (Suppl): 12-23.
- 3 Hay CR, Laurian Y, Verroust F, Preston FE, Kernoff PB. Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990; 76: 882-6.
- 4 Vyas P, Pasi J, Lee CA. Successful long-term treatment with porcine factor VIII of a patient with haemophilia and an inhibitor to factor VIII. Haemophilia 1996; 02: 240-3.
- 5 Messori A, Longo G, Matucci M, Morfini M, Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clinical Pharma-cokinet 1987; 13: 365-80.